693 matches
-
superiori. Șapca are aplicată în fața - la centru - pe banda, emblemă proprie. Pentru ținută de ceremonie șapca este de culoare albă. Pentru iarnă se poartă căciulă de croiala proprie. La ținută de instrucție sînt asigurate șepcuțe de croiala proprie, în cinci clini, de culoare neagră pentru forțele de intervenție și de culoare bleu închis pentru forțele de pază. B. Îmbrăcămintea Costume bleumarin, iar pentru ceremonie, de culoare albă, cusute la două rînduri. Pentru instrucție, veston cu pantalon de culoare neagră pentru forțele
EUR-Lex () [Corola-website/Law/108954_a_110283]
-
2005; 97: 1262-1271. 11. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-629. 12. https//www.adjuvantonline.com/breast.jsp. 13. NCCN Clinical Practice Guidelines în Oncology Breast Cancer. http:// www.nccn.org/professionals/physician gls/PDF/breast.pdf. 14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (Suppl 1): S3-S18. 18. Hershman DL, McMahon DJ, Crew KD et al. Zoledronic acid prevents bone loss în premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26: 4739-4745. Cancerul mamar recurent local sau metastatic Recomandări clinice pentru diagnosticare, tratament și urmărire Annals of Oncology 20 (Supplement 4): iv15-iv18, 2009 doi:10.1093/annonc/mdp115 F. Cardoso*1) amp; M. Castiglione*2) Din partea grupului de
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
al. Achievements în systemic therapies în the pre-genomic era în metastatic breast cancer. Oncologist 2007; 12: 253-270. 5. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin în patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354. 6. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy în anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823. 7
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354. 6. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy în anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823. 7. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy în patients with metastatic breast cancer and prior anthracycline treatment: final results of a global phase III study. J Clin Oncol
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
J Clin Oncol 2002; 20: 2812-2823. 7. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy în patients with metastatic breast cancer and prior anthracycline treatment: final results of a global phase III study. J Clin Oncol 2008; 26: 3950-3957. 8. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine în women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730. 9. Miller K, Wang M, Gralow J et
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
prior anthracycline treatment: final results of a global phase III study. J Clin Oncol 2008; 26: 3950-3957. 8. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine în women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730. 9. Miller K, Wang M, Gralow J et al. Paclitaxel pus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676. 10. Gennari A, Amadori D, De Lena M et al
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
pus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676. 10. Gennari A, Amadori D, De Lena M et al. Lack of benefit of maintenance paclitaxel în first-line chemotherapy în metastatic breast cancer. J Clin Oncol 2006; 24: 3912-3918. 11. Ghersi D, Wilcken N, Simes J et al. Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2003; 3: CD003366. Cancerul ovarian epitelial Recomandările ESMO pentru diagnostic, tratament și urmărire S. Aebi*1
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007; 104: 480-490. 4. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-1259. 5. du Bois A, Luck H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. JNCI Cancer Spectrum 2003; 95: 1320-1329. 6. Fader AN, Rose
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Luck H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. JNCI Cancer Spectrum 2003; 95: 1320-1329. 6. Fader AN, Rose PG. Role of surgery în ovarian carcinoma. J Clin Oncol 2007; 25:2873-2883. 7. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 2007; 8: 813-821. 8. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
for Gynaecological Cancers, 3rd edition. International Federation of Gynecology and Obstetrics 2000; 95-121; http://www.figo.org/docs/ staging booklet.pdf. 11. Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse în advanced ovarian cancer. J Clin Oncol 2006; 24: 1454-1458. 12. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel în patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel în patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465. 13. McGuire WP, Hoskins WJ, Brady ME et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin în patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6. 14. Ozols
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Med 1996; 334: 1-6. 14. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel în patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200. 15. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin în patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004; 351: 2489-2497. 18. Rustin GJ, Bast RC, Jr., Kelloff GJ et al. Use of CA-125 în clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004; 10: 3919-3926. 19. Rustin GJS, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-1551. 20. Trimbos JB, Parmar M, Vergote I
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
în clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004; 10: 3919-3926. 19. Rustin GJS, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-1551. 20. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy în Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy ��n patients with early-stage ovarian
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
cord stromal tumors of the ovary-an analysis of 376 women. Gynecol Oncol 2007; 104: 396-400. 8. Kurman RJ, Scardino PT, Waldmann TA et al. Malignant germ cell tumors of the ovary and testis: an immunohistologic study of 69 cases. Ann Clin Lab Sci 1979; 9: 462-466. 9. Obata NH, Nakashima N, Kawai M et al. Gonadoblastoma with dysgerminoma în one ovary and gonadoblastoma with dysgerminoma and yolk sac tumor în the contralateral ovary în a girl with 46XX karyotype. Gynecol Oncol
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
cell and sex-cord stromal tumors. Gynecol Oncol 1994; 55: S62-S72. 13. Bajorin DF, Sarosdy MF, Pfister GD et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin în patients with good-risk germ cell tumors: a mulți-instituțional study. J Clin Oncol 1993; 11: 598-606. 14. Homesley HD, Bundy BN, Hurteau JA et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 1999; 72: 131-137. 15. Williams
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 1999; 72: 131-137. 15. Williams SD, Blessing JA, Hatch KHomesley HD. Chemotherapy of advanced ovarian dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 1991; 9: 1950-1955. Annals of Oncology 20 (Supplement 4): iv24-iv26, 2009 doi:10.1093/annonc/mdp118 Cancerul de col uterin Recomandările ESMO pentru diagnosticare, tratament și monitorizare C. Haie-Meder*1), P. Morice*2) amp; M. Castiglione*3) Din partea Grupului
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
al. SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update buletin 2004. Ann Oncol 2005; 16: 1600-1608. 11. Lukka H, Hirte H, Fyles A et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-a meta-analysis. Clin Oncol 2002; 14: 203-212. 12. Girinsky T, Rey A, Roche B et al. Overall treatment time în advanced cervical carcinomas: a critical parameter în treatment outcome. Int J Radiat Oncol Biol Phys 1993; 27: 1051-1056. 13. Keys HM, Bundy TM
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
cancer: a systematic review. Gynecol Oncol 2006; 102: 361-368. 8. Hogberg T, Rosenberg P, Kristensen G et al. A randomized phase III study on adjuvant treatment with radiation 6 chemotherapy în early stage high-risk endometrial cancer (NSGO-EC9501/EORTC 55991). J Clin Oncol 2007; 25(18S): Abstr 5503. 9. Martin-Hirsch PPL, Jarvis GG, Kitchener HC. Lilford. Progestagens for endometrial cancer (Cochrane review). Cochrane Database Syst Rev 1999 (Issue 4); CD001040. 10. Lambrou NC, Go' mez-Mari'n O, Mirhashemi R et al. Optimal
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Gynaecological Cancer Group. Ann Oncol 2003; 14: 441-448. 12. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgastrim în advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 2159-2166. 13. Randall ME, Brunetto G, Muss HB et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy în advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. J Clin Oncol 2006; 24: 36-44
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Oncology Group study. J Clin Oncol 2004; 22: 2159-2166. 13. Randall ME, Brunetto G, Muss HB et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy în advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. J Clin Oncol 2006; 24: 36-44. Cancerul esofagian Recomandările ESMO pentru diagnosticare, tratament și urmărire M. Stahl*1) amp; J. Oliveira*2) Din partea Grupului de Lucru ESMO pentru Ghiduri Terapeutice*) *1) Department of Medical Oncology and Centre of Palliative Care, Kliniken Essen-Mitte
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
cancer therapy. N Engl J Med 2006; 354: 496-507. 3. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174. 4. Fiorca F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925-930. 5. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. 6. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery în patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317. 7. Sumpter K, Harper-Wynne C, Cunningham D et al. Report of two protocol planned interim analyses în a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin în patients with advanced oesophagogastric
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
în esophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234. 9. Bedenne L, Michel P, Bouche O et al. Randomized phase III trial în locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 2002; 21: 130a (Abstr 519). Cancerul gastric Recomandările ESMO pentru diagnosticare, tratament și monitorizare C. Jackson*1), D. Cunningham*1) amp; J. Oliveira*2) Din partea Grupului de Lucru ESMO pentru Ghiduri Terapeutice *1) Gastrointestinal Unit, Royal Marsden Hospital, Sutton
EUR-Lex () [Corola-website/Law/227406_a_228735]